Complication: mortality (up to 6 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula
Clopidogrel probably leads to higher complication: mortality (up to 6 months) compared with placebo (moderate certainty).
1 finding from 1 review
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula
Clopidogrel showed no clear difference in number of related surgical or radiological interventions (42 days) compared with placebo (moderate certainty).
1 finding from 1 review
Complications (28 days to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
1 finding from 1 review
Graft thrombosis (up to 3 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
Sulphinpyrazone showed no clear difference in graft thrombosis (up to 3 months) compared with placebo (low certainty).
1 finding from 1 review
Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications (up to 3 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fistula failure (6 weeks) · people with ESRD receiving haemodialysis through an arteriovenous fistula
Glyceryl trinitrate patch showed no clear difference in fistula failure (6 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications (6 weeks) · people with ESRD receiving haemodialysis through an arteriovenous fistula
1 finding from 1 review
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fistulae thromboses (up to 1 month) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
Ticlopidine probably leads to lower fistulae thromboses (up to 1 month) compared with placebo (moderate certainty).
1 finding from 1 review
Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications (up to 1 month) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
1 finding from 1 review
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft
Dipyridamole showed no clear difference in graft thrombosis (up to 18 months) compared with placebo (moderate certainty).
1 finding from 1 review
Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether total shunt changes mortality due to rebleeding compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether total shunt changes acute hepatic encephalopathy compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Chronic hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
1 finding from 1 review